Cost comparison of liraglutide and sitagliptin for type 2 diabetes not well controlled by metformin

The long-term economic value of liraglutide compared with sitagliptin is being assessed in patients with type 2 diabetes mellitus who do not achieve adequate glycemic control with metformin.

• Patients with type 2 diabetes mellitus often require additional medications when metformin alone is insufficient.
• Liraglutide and sitagliptin are both options for improving glycemic control in these patients.
• The economic implications of using liraglutide versus sitagliptin in this context are under evaluation.
• Understanding the cost-effectiveness of these treatments could inform clinical decisions and healthcare policy.

Simplified